UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 304

Sortiert nach

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American journal of clinical dermatology, 2021-09, Vol.22 (5), p.693-707

2021

Volltextzugriff (PDF)

The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?

Trends in pharmacological sciences (Regular ed.), 2013-06, Vol.34 (6), p.332-339

2013

Volltextzugriff (PDF)

The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific

Psychopharmacologia, 2007-04, Vol.191 (2), p.223-231

2007

Volltextzugriff (PDF)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Inflammatory bowel diseases, 2018-09, Vol.24 (10), p.2258-2265

2018

Volltextzugriff (PDF)

Differential Endocannabinoid Regulation of Extinction in Appetitive and Aversive Barnes Maze Tasks

Learning & memory (Cold Spring Harbor, N.Y.), 2008-11, Vol.15 (11), p.806-809

2008

Volltextzugriff (PDF)

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Clinical gastroenterology and hepatology, 2022-01, Vol.20 (1), p.116-125.e5

2022

Volltextzugriff (PDF)

Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies

Inflammatory bowel diseases, 2021-06, Vol.27 (7), p.983-993

2021

Volltextzugriff (PDF)

Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

American journal of clinical dermatology, 2024, Vol.25 (1), p.127-138

2024

Volltextzugriff (PDF)

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

Inflammatory bowel diseases, 2021-05, Vol.27 (6), p.816-825

2021

Volltextzugriff (PDF)

Modern Methods of Monosaccharide Synthesis from Non-Carbohydrate Sources

Chemical reviews, 1996-05, Vol.96 (3), p.1195-1220

1996

Volltextzugriff (PDF)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Journal of Crohn's and colitis, 2021-06, Vol.15 (6), p.914-929

2021

Volltextzugriff (PDF)

Hippocampal CB1 Receptors Mediate the Memory Impairing Effects of Δ9-Tetrahydrocannabinol

Neuropsychopharmacology (New York, N.Y.), 2009-03, Vol.34 (9), p.2072-2080

2009

Volltextzugriff (PDF)

Time to Loss of Efficacy Following Tofacitinib Interruption in Patients With Ulcerative Colitis: Results From OCTAVE Sustain: 725

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S405-S406

2018

Volltextzugriff (PDF)

Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study: 696

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S390-S391

2018

Volltextzugriff (PDF)

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American journal of clinical dermatology, 2021-11, Vol.22 (6), p.905-905

2021

Volltextzugriff (PDF)

Oxadiazolone bioisosteres of pregabalin and gabapentin

Bioorganic & medicinal chemistry letters, 2009, Vol.19 (1), p.247-250

2009

Volltextzugriff (PDF)

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment: 571

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S329-S329

2018

Volltextzugriff (PDF)

FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration

Neuropsychopharmacology (New York, N.Y.), 2010-07, Vol.35 (8), p.1775

2010

Volltextzugriff (PDF)

Structure−Activity Relationships of Pregabalin and Analogues That Target the α2-δ Protein

Journal of medicinal chemistry, 2005-04, Vol.48 (7), p.2294-2307

2005

Volltextzugriff (PDF)

Postoperative fluorescence bronchoscopic surveillance: a worthwhile procedure in a subset of patients

The Annals of thoracic surgery, 2002, Vol.73 (1), p.348-348

2002

Volltextzugriff (PDF)

Current status and future perspectives of cyclohexadiene-cis-diols in organic synthesis: versatile intermediates in the concise design of natural products

Chemical communications (Cambridge, England), 1996 (17), p.1993

1996

Volltextzugriff (PDF)

Novel Cyclopropyl β-Amino Acid Analogues of Pregabalin and Gabapentin That Target the α2-δ Protein

Journal of medicinal chemistry, 2005-04, Vol.48 (8), p.3026-3035

2005

Volltextzugriff (PDF)

Tu1874 MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: UPDATED RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1198-S-1199

2020

Volltextzugriff (PDF)

The role of photodynamic therapy (PDT) in inoperable oesophageal cancer

European journal of cardio-thoracic surgery, 2000-02, Vol.17 (2), p.95-100

2000

Volltextzugriff (PDF)

Tu1857 TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1190-S-1191

2020

Volltextzugriff (PDF)

1 – 25 von 304

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(267)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(204)
Life Sciences & Biomedicine
(169)
Humans
(114)
Female
(61)
Male
(60)
Biological And Medical Sciences
(41)
Aged
(35)
Middle Aged
(35)
Physical Sciences
(34)
Treatment Outcome
(29)
Adult
(28)
Animals
(27)
Medical Sciences
(24)
Fundamental And Applied Biological Sciences. Psychology
(22)
Urology & Nephrology
(22)
General & Internal Medicine
(20)
Patients
(20)
Cardiovascular System & Cardiology
(19)
Medicine, General & Internal
(18)
Retrospective Studies
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?

The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Differential Endocannabinoid Regulation of Extinction in Appetitive and Aversive Barnes Maze Tasks

Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis

Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies

Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2

Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program

Modern Methods of Monosaccharide Synthesis from Non-Carbohydrate Sources

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Hippocampal CB1 Receptors Mediate the Memory Impairing Effects of Δ9-Tetrahydrocannabinol

Time to Loss of Efficacy Following Tofacitinib Interruption in Patients With Ulcerative Colitis: Results From OCTAVE Sustain: 725

Maintenance of Remission With Tofacitinib in Patients With Ulcerative Colitis: Subpopulation Analysis From an Open-Label, Long-Term Extension Study: 696

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Oxadiazolone bioisosteres of pregabalin and gabapentin

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Ulcerative Colitis: An Interim Analysis of an Open-Label, Long-Term Extension Study With up to 4.9 Years of Treatment: 571

FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration

Structure−Activity Relationships of Pregabalin and Analogues That Target the α2-δ Protein

Postoperative fluorescence bronchoscopic surveillance: a worthwhile procedure in a subset of patients

Current status and future perspectives of cyclohexadiene-cis-diols in organic synthesis: versatile intermediates in the concise design of natural products

Novel Cyclopropyl β-Amino Acid Analogues of Pregabalin and Gabapentin That Target the α2-δ Protein

Tu1874 MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: UPDATED RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

The role of photodynamic therapy (PDT) in inoperable oesophageal cancer

Tu1857 TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT

Suchergebnisse filtern